Drug delivery: Brushing off antigenicity

Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015)

(2016) Eun Ji Park et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

The Mystery of Antibodies Against Polyethylene Glycol (PEG) - What do we Know?

(2016) Christian Lubich et al.   PHARMACEUTICAL RESEARCH

A brush-polymer/exendin-4 conjugate reduces blood glucose levels for up to five days and eliminates poly(ethylene glycol) antigenicity

(2016) Yizhi Qi et al.   Nature Biomedical Engineering

What is the future of PEGylated therapies?

(2015) Magdalena Swierczewska et al.   EXPERT OPINION ON EMERGING DRUGS

Biopharmaceutical benchmarks 2014

(2014) Gary Walsh   NATURE BIOTECHNOLOGY

Site-Specific PEGylated Exendin-4 Modified with a High Molecular Weight Trimeric PEG Reduces Steric Hindrance and Increases Type 2 Antidiabetic Therapeutic Effects

(2012) Tae Hyung Kim et al.   BIOCONJUGATE CHEMISTRY

Protein therapeutics: a summary and pharmacological classification

(2007) Benjamin Leader et al.   NATURE REVIEWS DRUG DISCOVERY